Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:EDIT NASDAQ:NTLA NYSE:NVS NASDAQ:REGN NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$47.65-1.9%$51.31$35.38▼$78.48$4.61B1.741.85 million shs636,413 shsEDITEditas Medicine$2.50-1.4%$2.78$1.47▼$4.54$245.27M2.141.63 million shs318,407 shsNTLAIntellia Therapeutics$12.14-4.4%$13.62$6.83▼$28.25$1.71B1.935.52 million shs2.25 million shsNVSNovartis$150.88+1.2%$150.74$111.06▼$170.46$288.28B0.462.00 million shs318,054 shsREGNRegeneron Pharmaceuticals$632.69+0.5%$741.98$476.49▼$821.11$66.98B0.3771,400 shs309,673 shsVRTXVertex Pharmaceuticals$443.37+1.6%$445.08$362.50▼$507.92$112.64B0.31.37 million shs227,861 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+0.31%-10.09%-16.26%-8.67%+25.25%EDITEditas Medicine-3.44%-17.32%-27.51%+45.40%+67.55%NTLAIntellia Therapeutics-7.17%-12.00%-15.12%+3.85%+49.29%NVSNovartis+0.71%+2.72%-1.94%-10.23%+36.04%REGNRegeneron Pharmaceuticals-9.82%-11.66%-16.11%-20.65%+5.95%VRTXVertex Pharmaceuticals-0.08%+0.32%-1.05%-8.54%-0.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$47.65-1.9%$51.31$35.38▼$78.48$4.61B1.741.85 million shs636,413 shsEDITEditas Medicine$2.50-1.4%$2.78$1.47▼$4.54$245.27M2.141.63 million shs318,407 shsNTLAIntellia Therapeutics$12.14-4.4%$13.62$6.83▼$28.25$1.71B1.935.52 million shs2.25 million shsNVSNovartis$150.88+1.2%$150.74$111.06▼$170.46$288.28B0.462.00 million shs318,054 shsREGNRegeneron Pharmaceuticals$632.69+0.5%$741.98$476.49▼$821.11$66.98B0.3771,400 shs309,673 shsVRTXVertex Pharmaceuticals$443.37+1.6%$445.08$362.50▼$507.92$112.64B0.31.37 million shs227,861 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+0.31%-10.09%-16.26%-8.67%+25.25%EDITEditas Medicine-3.44%-17.32%-27.51%+45.40%+67.55%NTLAIntellia Therapeutics-7.17%-12.00%-15.12%+3.85%+49.29%NVSNovartis+0.71%+2.72%-1.94%-10.23%+36.04%REGNRegeneron Pharmaceuticals-9.82%-11.66%-16.11%-20.65%+5.95%VRTXVertex Pharmaceuticals-0.08%+0.32%-1.05%-8.54%-0.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.53Moderate Buy$65.4737.41% UpsideEDITEditas Medicine 2.57Moderate Buy$5.40116.43% UpsideNTLAIntellia Therapeutics 2.35Hold$20.2566.87% UpsideNVSNovartis 2.31Hold$141.20-6.42% DownsideREGNRegeneron Pharmaceuticals 2.70Moderate Buy$792.6525.28% UpsideVRTXVertex Pharmaceuticals 2.85Moderate Buy$555.1725.22% UpsideCurrent Analyst Ratings BreakdownLatest EDIT, NTLA, VRTX, CRSP, NVS, and REGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026REGNRegeneron Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1,057.00 ➝ $875.005/18/2026REGNRegeneron Pharmaceuticals BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$900.00 ➝ $730.005/18/2026REGNRegeneron Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$796.00 ➝ $778.005/18/2026REGNRegeneron Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$950.00 ➝ $850.005/18/2026REGNRegeneron Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$762.00 ➝ $707.005/18/2026REGNRegeneron Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$800.00 ➝ $700.005/18/2026REGNRegeneron Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$875.00 ➝ $855.005/18/2026REGNRegeneron Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$900.00 ➝ $700.005/18/2026REGNRegeneron Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$792.00 ➝ $641.005/13/2026NTLAIntellia Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$13.00 ➝ $17.005/13/2026CRSPCRISPR Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$50.00 ➝ $56.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$3.51M1,309.22N/AN/A$20.17 per share2.36EDITEditas Medicine$40.52M6.03N/AN/A$0.28 per share8.91NTLAIntellia Therapeutics$67.67M25.06N/AN/A$5.80 per share2.09NVSNovartis$54.53B5.28$10.94 per share13.79$22.04 per share6.85REGNRegeneron Pharmaceuticals$14.92B4.48$38.04 per share16.63$295.66 per share2.14VRTXVertex Pharmaceuticals$12.00B9.38$17.83 per share24.86$73.57 per share6.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)EDITEditas Medicine-$160.06M-$1.23N/AN/AN/A-281.59%-677.39%-58.25%N/ANTLAIntellia Therapeutics-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)NVSNovartis$13.98B$6.9821.6415.352.6024.87%38.82%15.16%7/21/2026 (Estimated)REGNRegeneron Pharmaceuticals$4.50B$41.0415.4415.241.5529.65%13.16%10.17%7/30/2026 (Estimated)VRTXVertex Pharmaceuticals$3.95B$16.8626.3223.311.8735.51%23.86%17.13%8/3/2026 (Estimated)Latest EDIT, NTLA, VRTX, CRSP, NVS, and REGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026NTLAIntellia Therapeutics-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million5/5/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 million5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million5/4/2026Q1 2026VRTXVertex Pharmaceuticals$4.24$4.47+$0.23$4.02$2.99 billion$2.99 billion4/29/2026Q1 2026REGNRegeneron Pharmaceuticals$8.91$9.47+$0.56$6.75$3.48 billion$3.61 billion4/27/2026Q1 2026NVSNovartis$2.11$1.99-$0.12$1.65$13.44 billion$13.52 billion3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 million3/9/2026Q4 2025EDITEditas Medicine-$0.27-$0.06+$0.21-$0.06$8.77 million$24.74 million2/26/2026Q4 2025NTLAIntellia Therapeutics-$0.99-$0.83+$0.16-$0.83$12.17 million$23.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ANVSNovartis$3.082.04%+5.28%44.13%N/AREGNRegeneron Pharmaceuticals$3.760.59%N/A9.16%N/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest EDIT, NTLA, VRTX, CRSP, NVS, and REGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026REGNRegeneron Pharmaceuticalsquarterly$0.940.55%5/20/20265/20/20266/4/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR Therapeutics0.3217.9717.96EDITEditas MedicineN/A3.223.22NTLAIntellia TherapeuticsN/A6.106.10NVSNovartis0.960.850.65REGNRegeneron Pharmaceuticals0.063.572.96VRTXVertex PharmaceuticalsN/A3.022.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%EDITEditas Medicine71.90%NTLAIntellia Therapeutics88.77%NVSNovartis13.12%REGNRegeneron Pharmaceuticals83.31%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.10%EDITEditas Medicine3.10%NTLAIntellia Therapeutics3.10%NVSNovartis0.01%REGNRegeneron Pharmaceuticals6.97%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46096.45 million92.50 millionOptionableEDITEditas Medicine23097.91 million94.87 millionOptionableNTLAIntellia Therapeutics600139.72 million135.39 millionOptionableNVSNovartis75,2671.91 billion1.91 billionOptionableREGNRegeneron Pharmaceuticals15,410105.72 million98.35 millionOptionableVRTXVertex Pharmaceuticals6,400253.80 million253.30 millionOptionableEDIT, NTLA, VRTX, CRSP, NVS, and REGN HeadlinesRecent News About These CompaniesVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It1 hour ago | zacks.comVertex Pharmaceuticals Incorporated $VRTX Holdings Decreased by Tredje AP fonden4 hours ago | marketbeat.comResona Asset Management Co. Ltd. Has $40.63 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX4 hours ago | marketbeat.comProfund Advisors LLC Purchases 2,423 Shares of Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 6:18 AM | marketbeat.comProShare Advisors LLC Grows Stake in Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 6:18 AM | marketbeat.comAMF Tjanstepension AB Buys 83,487 Shares of Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 3:11 AM | marketbeat.comVertex Steps Into Autoimmune Care: Mid-Stage Myasthenia Gravis Trial Shows Growing Pipeline AmbitionMay 18 at 12:50 PM | tipranks.comNorth Dakota State Investment Board Buys Shares of 8,821 Vertex Pharmaceuticals Incorporated $VRTXMay 18 at 5:49 AM | marketbeat.comCanada Post Corp Registered Pension Plan Has $2.94 Million Stake in Vertex Pharmaceuticals Incorporated $VRTXMay 18 at 3:57 AM | marketbeat.comFY2026 Earnings Estimate for VRTX Issued By Erste Group BankMay 18 at 1:23 AM | marketbeat.comLeuthold Group LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTXMay 17 at 6:49 AM | marketbeat.comSTF Management LP Lowers Position in Vertex Pharmaceuticals Incorporated $VRTXMay 17 at 6:25 AM | marketbeat.comInsider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Sells $3,144,600.00 in StockMay 17 at 4:37 AM | americanbankingnews.comVertex Pharmaceuticals Incorporated $VRTX Shares Purchased by DNB Asset Management ASMay 16 at 4:39 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Recommendation of "Moderate Buy" by AnalystsMay 16 at 3:27 AM | marketbeat.comAllworth Financial LP Has $6.36 Million Position in Vertex Pharmaceuticals Incorporated $VRTXMay 16 at 3:15 AM | marketbeat.comVertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitorsMay 15, 2026 | marketwatch.comVRTX Stock Down as Q1 Sales of New Drugs Miss ExpectationsMay 15, 2026 | msn.comFY2027 Earnings Forecast for VRTX Issued By Erste Group BankMay 15, 2026 | marketbeat.comInsider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Sells 6,988 Shares of StockMay 15, 2026 | insidertrades.comVertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Atria Investments IncMay 15, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAs Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026NerdWallet’s Growth Story Looks Strong—But Can It Last?By Peter Frank | April 30, 2026Viking Sails to All-Time Highs—Fundamentals Signal More to ComeBy Chris Markoch | May 15, 2026Capital One’s Big Bet Faces Rising Credit RiskBy Peter Frank | May 6, 2026EDIT, NTLA, VRTX, CRSP, NVS, and REGN Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$47.64 -0.92 (-1.88%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Editas Medicine NASDAQ:EDIT$2.50 -0.04 (-1.38%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Intellia Therapeutics NASDAQ:NTLA$12.14 -0.56 (-4.37%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Novartis NYSE:NVS$150.88 +1.73 (+1.16%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Regeneron Pharmaceuticals NASDAQ:REGN$632.68 +3.01 (+0.48%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Vertex Pharmaceuticals NASDAQ:VRTX$443.37 +6.79 (+1.55%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings Rewiring AI: NextEra Energy Sparks a Mega Merger Flipping the Switch: Is Ford the Next Big Energy Stock? Does Nano Nuclear Energy’s New Deal Amp the Outlook? Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade? Why Trump’s Amazon Stock Sale May Not Matter at All Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
